IL275720B - Use of semaphorin-4d binding molecules for treating neurodegenerative disorders - Google Patents
Use of semaphorin-4d binding molecules for treating neurodegenerative disordersInfo
- Publication number
- IL275720B IL275720B IL275720A IL27572020A IL275720B IL 275720 B IL275720 B IL 275720B IL 275720 A IL275720 A IL 275720A IL 27572020 A IL27572020 A IL 27572020A IL 275720 B IL275720 B IL 275720B
- Authority
- IL
- Israel
- Prior art keywords
- antibody
- antigen
- binding fragment
- seq
- nos
- Prior art date
Links
- 108010056102 CD100 antigen Proteins 0.000 title claims 6
- 102100027744 Semaphorin-4D Human genes 0.000 title claims 6
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
- 239000000427 antigen Substances 0.000 claims 21
- 102000036639 antigens Human genes 0.000 claims 21
- 108091007433 antigens Proteins 0.000 claims 21
- 239000012634 fragment Substances 0.000 claims 21
- 208000024827 Alzheimer disease Diseases 0.000 claims 4
- 210000002569 neuron Anatomy 0.000 claims 3
- 102100034384 Plexin-B1 Human genes 0.000 claims 2
- 101710100559 Plexin-B1 Proteins 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 102100025218 B-cell differentiation antigen CD72 Human genes 0.000 claims 1
- 101000934359 Homo sapiens B-cell differentiation antigen CD72 Proteins 0.000 claims 1
- 206010061296 Motor dysfunction Diseases 0.000 claims 1
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 claims 1
- 102100034383 Plexin-B2 Human genes 0.000 claims 1
- 101710100551 Plexin-B2 Proteins 0.000 claims 1
- 102000005157 Somatostatin Human genes 0.000 claims 1
- 108010056088 Somatostatin Proteins 0.000 claims 1
- 230000007529 anxiety like behavior Effects 0.000 claims 1
- 210000001130 astrocyte Anatomy 0.000 claims 1
- 230000003920 cognitive function Effects 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 230000033001 locomotion Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims 1
- 229960000553 somatostatin Drugs 0.000 claims 1
- 230000000946 synaptic effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (12)
1. An effective amount of an isolated antibody or an antigen-binding fragment thereof that specifically binds to semaphorin-4D (SEMA4D) for use in alleviating symptoms selected from neuropsychiatric symptoms, cognitive symptoms, motor dysfunction, or any combination thereof in a subject having, determined to have or suspected of having Alzheimer’s Disease (AD), wherein the antibody or antigen-binding fragment thereof inhibits SEMA4D interaction with its receptor or a portion of its receptor; wherein the use of the antibody or an antigen-binding fragment thereof alleviates anxiety-like behavior, improves cognitive function, improves locomotion, or any combination thereof in the subject.
2. The antibody or antigen-binding fragment thereof for the use of claim 1, wherein the AD is early AD.
3. The antibody or antigen-binding fragment thereof for the use of claim 1 or 2, wherein the receptor is selected from the group consisting of Plexin-B1, Plexin-B2, and CD72.
4. The antibody or antigen-binding fragment thereof for the use of any one of claims 1 to 3, wherein the antibody or antigen-binding fragment thereof inhibits SEMA4D-mediated Plexin-B1 signal transduction.
5. The antibody or antigen-binding fragment thereof for the use of any one of claims 1 to 5, wherein the antibody or antigen-binding fragment thereof competitively inhibits a reference monoclonal antibody comprising a variable heavy chain (VH) comprising VHCDRs 1-3 comprising SEQ ID NOs 6, 7, and 8, respectively, and a variable light chain (VL) comprising VLCDRs 1-3 comprising SEQ ID NOs 14, 15, and 16, respectively.
6. The antibody or antigen-binding fragment thereof for the use of any one of claims 1 to 5, wherein the antibody or antigen-binding fragment thereof specifically binds to the same SEMA4D epitope as a reference monoclonal antibody comprising a variable heavy chain (VH) comprising VHCDRs 1-3 comprising SEQ ID NOs 6, 7, and 8, respectively, and a variable light chain (VL) comprising VLCDRs 1-3 comprising SEQ ID NOs 14, 15, and 16, respectively.
7. The antibody or antigen-binding fragment thereof for the use of any one of claims 1 to 6, wherein the antibody or antigen-binding fragment thereof is a monoclonal antibody 4858-1143-3745, v. comprising a variable heavy chain (VH) comprising VHCDRs 1-3 comprising SEQ ID NOs 6, 7, and 8, respectively, and a variable light chain (VL) comprising VLCDRs 1-comprising SEQ ID NOs 14, 15, and 16, respectively.
8. The antibody or antigen-binding fragment thereof for the use of any one of claims 1 to 7, wherein the antibody or antigen-binding fragment thereof is a monoclonal antibody comprising a variable heavy chain (VH)and a variable light chain (VL) wherein the VH and VL comprise, respectively, SEQ ID NO: 9 and SEQ ID NO: 17 or SEQ ID NO: and SEQ ID NO: 18.
9. The antibody or antigen-binding fragment thereof for the use of any one of claims 1 to 8, wherein the subject is human.
10. The antibody or antigen-binding fragment thereof for the use of any one of claims 1-9, wherein the antibody or antigen-binding fragment thereof modulates astrocyte-mediated synaptic activity.
11. The antibody or antigen-binding fragment thereof for the use of any one of claims 1-10, wherein the antibody or antigen-binding fragment thereof protects inhibitory neurons from degeneration.
12. The method of any one of claims 1 to 11, wherein the antibody or antigen-binding fragment thereof restores the number of somatostatin positive neurons, NYP-positive neurons, or both in the subject.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361893814P | 2013-10-21 | 2013-10-21 | |
| US201461979384P | 2014-04-14 | 2014-04-14 | |
| US201462012805P | 2014-06-16 | 2014-06-16 | |
| PCT/US2014/061592 WO2015061330A1 (en) | 2013-10-21 | 2014-10-21 | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL275720A IL275720A (en) | 2020-08-31 |
| IL275720B true IL275720B (en) | 2022-09-01 |
Family
ID=52826380
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL295045A IL295045B2 (en) | 2013-10-21 | 2014-10-21 | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| IL275720A IL275720B (en) | 2013-10-21 | 2014-10-21 | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| IL245089A IL245089B (en) | 2013-10-21 | 2016-04-13 | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL295045A IL295045B2 (en) | 2013-10-21 | 2014-10-21 | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL245089A IL245089B (en) | 2013-10-21 | 2016-04-13 | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US9598495B2 (en) |
| EP (2) | EP3639853A1 (en) |
| JP (2) | JP6461944B2 (en) |
| KR (4) | KR20230159633A (en) |
| CN (2) | CN116966293A (en) |
| AU (3) | AU2014340210B2 (en) |
| BR (1) | BR112016009047B1 (en) |
| CA (2) | CA2927841C (en) |
| DK (1) | DK3060252T3 (en) |
| EA (1) | EA033072B1 (en) |
| ES (1) | ES2773961T3 (en) |
| IL (3) | IL295045B2 (en) |
| MX (2) | MX2016005050A (en) |
| NZ (1) | NZ630892A (en) |
| PL (1) | PL3060252T3 (en) |
| PT (1) | PT3060252T (en) |
| SG (2) | SG10201707786QA (en) |
| WO (1) | WO2015061330A1 (en) |
| ZA (1) | ZA201602686B (en) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6059013B2 (en) | 2009-05-08 | 2017-01-11 | バクシネックス インコーポレーティッド | Anti-CD100 antibodies and methods for using the same |
| SG11201401458UA (en) | 2011-10-11 | 2014-07-30 | Vaccinex Inc | Use of semaphorin-4d binding molecules for modulation of blood brain barrier permeability |
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| WO2014116982A2 (en) * | 2013-01-25 | 2014-07-31 | Brandeis University | Methods of modulating gabaergic inhibitory synapse formation and function |
| CA2916245C (en) | 2013-06-25 | 2023-01-24 | Vaccinex, Inc. | Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases |
| NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
| NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| MX2018012818A (en) | 2016-04-22 | 2019-07-04 | Vaccinex Inc | Integral membrane protein display on poxvirus extracellular enveloped virions. |
| IL264343B2 (en) | 2016-08-02 | 2024-05-01 | Vaccinex Inc | Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells |
| JP7084689B2 (en) * | 2016-12-08 | 2022-06-15 | 公益財団法人東京都医学総合研究所 | Methods for producing non-human animals with abnormalities in brain tissue and their use |
| SG11201906670PA (en) * | 2017-02-22 | 2019-08-27 | Vaccinex Inc | Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases |
| JP7159187B2 (en) * | 2017-03-20 | 2022-10-24 | バクシネックス インコーポレーティッド | Methods of treating cancer using combinations of semaphorin-4D antibodies and epigenetic modulators |
| EP3618865A4 (en) | 2017-05-05 | 2021-05-05 | Vaccinex, Inc. | Human anti-semaphorin 4d antibody |
| CN109410218B (en) * | 2018-10-08 | 2020-08-11 | 百度在线网络技术（北京）有限公司 | Method and apparatus for generating vehicle damage information |
| EP3693380A1 (en) * | 2019-02-11 | 2020-08-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Dual inhibition of plexin-b1 and plexin-b2 |
| US11597765B2 (en) | 2020-06-25 | 2023-03-07 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules for the treatment of Rett syndrome |
| WO2022137964A1 (en) * | 2020-12-23 | 2022-06-30 | 国立大学法人大阪大学 | Pharmaceutical composition for preventing or treating cartilage/bone/joint diseases, and method for screening drug for preventing or treating cartilage/bone/joint diseases |
| WO2023048726A1 (en) * | 2021-09-27 | 2023-03-30 | Vaccinex, Inc. | Predictive outcome profiling for use of an anti-semaphorin-4d binding molecule to treat neurodegenerative disorders |
| US20230331863A1 (en) | 2022-02-13 | 2023-10-19 | Vaccinex, Inc. | Combination therapy with semaphorin-4d blockade and htt-lowering agent for treatment of huntington's disease |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013055922A1 (en) * | 2011-10-11 | 2013-04-18 | Vaccinex, Inc. | Use of semaphorin-4d binding molecules for modulation of blood brain barrier permeability |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ201918A (en) | 1981-09-18 | 1987-04-30 | Genentech Inc | N-terminal methionyl analogues of bovine growth hormone |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US5070192A (en) | 1988-03-23 | 1991-12-03 | The Johns Hopkins University | Cloned human topoisomerase i: cdna expression, and use for autoantibody detection |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| DE69133566T2 (en) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Formation of xenogenic antibodies |
| US6497872B1 (en) | 1991-07-08 | 2002-12-24 | Neurospheres Holdings Ltd. | Neural transplantation using proliferated multipotent neural stem cells and their progeny |
| FR2686087A1 (en) | 1992-01-13 | 1993-07-16 | Inst Nat Sante Rech Med | NOVEL LYMPHOCYTATIC ANTIGEN, CORRESPONDING ANTIBODIES AND THEIR APPLICATIONS. |
| US5639856A (en) | 1993-09-13 | 1997-06-17 | The Regents Of The University Of California | Semaphorin gene family |
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US6576754B2 (en) | 1995-11-09 | 2003-06-10 | Dana-Farber Cancer Institute | CD100 antigen and uses therefor |
| ES2273415T3 (en) | 1997-04-07 | 2007-05-01 | Genentech, Inc. | ANTI-VEGF ANTIBODIES. |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| AU6897998A (en) | 1997-04-11 | 1998-11-11 | Dendreon Corporation | Composition and method for inducing an immune response against tumour-rela ted antigens |
| EP0892047A3 (en) | 1997-07-09 | 2000-03-08 | Hoechst Marion Roussel Deutschland GmbH | Human and murine semaphorin L |
| US5968829A (en) | 1997-09-05 | 1999-10-19 | Cytotherapeutics, Inc. | Human CNS neural stem cells |
| US6638501B1 (en) | 1997-09-29 | 2003-10-28 | Neurospheres Holdings Ltd. | Use of multipotent neural stem cell progeny to augment non-neural tissues |
| US5958767A (en) | 1998-08-14 | 1999-09-28 | The Children's Medical Center Corp. | Engraftable human neural stem cells |
| DE69839970D1 (en) | 1998-11-10 | 2008-10-16 | Univ Rochester | METHODS FOR GENBAN PRODUCTION |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
| JP3787473B2 (en) | 1999-11-30 | 2006-06-21 | 独立行政法人科学技術振興機構 | Semaphorin receptor |
| WO2001046384A2 (en) | 1999-12-23 | 2001-06-28 | Cornell Research Foundation, Inc. | A method for isolating and purifying multipotential neural progenitor cells and multipotential neural progenitor cells |
| US6635742B1 (en) | 2000-01-25 | 2003-10-21 | Nuvelo, Inc. | Antibodies specific for semaphorin-like polypeptides |
| DE60233509D1 (en) | 2001-06-20 | 2009-10-08 | Fibron Ltd | FGFR3 BLOCKING ANTIBODIES, METHOD OF SCREENING THEREOF AND USES THEREOF |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| EP1365018A1 (en) | 2002-05-23 | 2003-11-26 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | CD100 semaphorin in myelination |
| AU2003232456B2 (en) | 2002-05-30 | 2009-06-04 | Macrogenics, Inc. | CD16A binding proteins and use for the treatment of immune disorders |
| EP1442749A1 (en) | 2003-01-31 | 2004-08-04 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system |
| CA2526085A1 (en) | 2003-05-30 | 2005-01-06 | Genentech, Inc. | Treatment with anti-vegf antibodies |
| EP2336178A1 (en) | 2003-12-11 | 2011-06-22 | Genentech, Inc. | Methods and compositions for inhibiting C-Met dimerization and activation |
| DK1773885T3 (en) | 2004-08-05 | 2010-08-16 | Genentech Inc | Humanized anti-c-met antagonists |
| US20060147449A1 (en) * | 2004-11-15 | 2006-07-06 | Brass Lawrence F | Method of using CD100 (or Sema4D) to mediate platelet activation and inflammatory responses |
| AU2006235271B2 (en) | 2005-04-07 | 2011-05-19 | Novartis Vaccines And Diagnostics Inc. | SEMA4D in cancer diagnosis, detection and treatment |
| JP2007308465A (en) | 2006-05-15 | 2007-11-29 | Boehringer Ingelheim Internatl Gmbh | Method for treatment of inflammatory disease, autoimmune disease or bone resorption abnormality |
| US7919594B2 (en) | 2007-02-14 | 2011-04-05 | Vaccinex, Inc. | Human anti-CD100 antibodies |
| TW200934512A (en) | 2008-01-10 | 2009-08-16 | Genentech Inc | PLEXIND1 agonists and their use |
| JP6059013B2 (en) | 2009-05-08 | 2017-01-11 | バクシネックス インコーポレーティッド | Anti-CD100 antibodies and methods for using the same |
| JP5797190B2 (en) | 2009-05-15 | 2015-10-21 | アイ アール エックス セーラピューティクス， インコーポレイテッド | Vaccine immunotherapy |
| AU2011267869A1 (en) | 2010-06-14 | 2013-01-10 | Vaccinex, Inc. | Anti-VEGF antibodies and uses thereof |
| JP5925768B2 (en) | 2011-05-13 | 2016-05-25 | 国立大学法人 東京医科歯科大学 | Bone formation promoter |
| US8790652B2 (en) | 2011-12-06 | 2014-07-29 | Vaccinex, Inc. | Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis |
| US9090709B2 (en) | 2012-03-28 | 2015-07-28 | Vaccinex, Inc. | Anti-SEMA4D antibodies and epitopes |
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| CA2916245C (en) | 2013-06-25 | 2023-01-24 | Vaccinex, Inc. | Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases |
| NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
| NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| MX2018012818A (en) | 2016-04-22 | 2019-07-04 | Vaccinex Inc | Integral membrane protein display on poxvirus extracellular enveloped virions. |
| IL264343B2 (en) | 2016-08-02 | 2024-05-01 | Vaccinex Inc | Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells |
| SG11201906670PA (en) | 2017-02-22 | 2019-08-27 | Vaccinex Inc | Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases |
-
2014
- 2014-09-11 NZ NZ630892A patent/NZ630892A/en unknown
- 2014-10-21 PT PT148550742T patent/PT3060252T/en unknown
- 2014-10-21 WO PCT/US2014/061592 patent/WO2015061330A1/en active Application Filing
- 2014-10-21 US US14/519,965 patent/US9598495B2/en active Active
- 2014-10-21 CA CA2927841A patent/CA2927841C/en active Active
- 2014-10-21 IL IL295045A patent/IL295045B2/en unknown
- 2014-10-21 JP JP2016524999A patent/JP6461944B2/en active Active
- 2014-10-21 SG SG10201707786QA patent/SG10201707786QA/en unknown
- 2014-10-21 KR KR1020237038769A patent/KR20230159633A/en active Search and Examination
- 2014-10-21 KR KR1020227025504A patent/KR102602502B1/en active IP Right Grant
- 2014-10-21 AU AU2014340210A patent/AU2014340210B2/en active Active
- 2014-10-21 CN CN202310282388.8A patent/CN116966293A/en active Pending
- 2014-10-21 EA EA201690813A patent/EA033072B1/en unknown
- 2014-10-21 PL PL14855074T patent/PL3060252T3/en unknown
- 2014-10-21 EP EP19208515.7A patent/EP3639853A1/en active Pending
- 2014-10-21 EP EP14855074.2A patent/EP3060252B1/en active Active
- 2014-10-21 KR KR1020217030075A patent/KR20210118246A/en not_active Application Discontinuation
- 2014-10-21 CA CA3193983A patent/CA3193983A1/en active Pending
- 2014-10-21 KR KR1020167013445A patent/KR102308493B1/en active IP Right Grant
- 2014-10-21 SG SG11201603167YA patent/SG11201603167YA/en unknown
- 2014-10-21 DK DK14855074.2T patent/DK3060252T3/en active
- 2014-10-21 IL IL275720A patent/IL275720B/en unknown
- 2014-10-21 MX MX2016005050A patent/MX2016005050A/en active IP Right Grant
- 2014-10-21 CN CN201480070232.2A patent/CN106029093B/en active Active
- 2014-10-21 ES ES14855074T patent/ES2773961T3/en active Active
- 2014-10-21 BR BR112016009047-0A patent/BR112016009047B1/en active IP Right Grant
-
2015
- 2015-06-29 US US14/753,882 patent/US9249227B2/en active Active
-
2016
- 2016-04-13 IL IL245089A patent/IL245089B/en active IP Right Grant
- 2016-04-19 ZA ZA201602686A patent/ZA201602686B/en unknown
- 2016-04-19 MX MX2020009260A patent/MX2020009260A/en unknown
-
2017
- 2017-03-21 US US15/465,509 patent/US10385136B2/en active Active
-
2018
- 2018-12-26 JP JP2018241924A patent/JP6875363B2/en active Active
-
2019
- 2019-07-02 US US16/460,593 patent/US10800853B2/en active Active
- 2019-10-28 AU AU2019257379A patent/AU2019257379B2/en active Active
-
2021
- 2021-04-06 AU AU2021202095A patent/AU2021202095B9/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013055922A1 (en) * | 2011-10-11 | 2013-04-18 | Vaccinex, Inc. | Use of semaphorin-4d binding molecules for modulation of blood brain barrier permeability |
Non-Patent Citations (3)
| Title |
|---|
| MASTERMAN, DONNA., TREATMENT OF THE NEUROPSYCHIATRIC SYMPTOMS IN ALZHEIMER'S DISEASE, 1 November 2013 (2013-11-01) * |
| PALMER, ALAN M., THE ROLE OF THE BLOOD BRAIN BARRIER IN NEURODEGENERATIVE DISORDERS AND THEIR TREATMENT., 1 January 2011 (2011-01-01) * |
| SRIKANTH, S.; NAGARAJA, A. V.; RATNAVALLI, E., NEUROPSYCHIATRIC SYMPTOMS IN DEMENTIA-FREQUENCY, RELATIONSHIP TO DEMENTIA SEVERITY AND COMPARISON IN ALZHEIMER'S DISEASE, VASCULAR DEMENTIA AND FRONTOTEMPORAL DEMENTIA, 15 September 2005 (2005-09-15) * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL275720B (en) | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders | |
| PH12018502623A1 (en) | Anti-pd-l1 antibodies and uses thereof | |
| WO2016207304A3 (en) | Monoclonal anti-il-1racp antibodies | |
| HRP20191342T1 (en) | Anti-phf-tau antibodies and their uses | |
| MA42542B1 (en) | Molecules Binding to pd-1 and Corresponding Methods of Use | |
| PH12020551173A1 (en) | Anti-pd-l1 antibodies and uses thereof | |
| NZ630610A (en) | Tau peptides, anti-tau antibodies, and methods of use thereof | |
| NZ628528A (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| NZ588713A (en) | Antibodies to receptor of advanced glycation end products (rage) and uses thereof | |
| WO2008019061A3 (en) | Anti-il-6 monoclonal antibodies and uses thereof | |
| WO2015200806A3 (en) | Humanized anti-tau antibodies | |
| PH12013502068A1 (en) | Monoclonal antibodies against the rgm a protein and uses thereof | |
| WO2010095031A3 (en) | Humanized antibodies that bind to cd19 and their uses | |
| JP2017502920A5 (en) | ||
| WO2009048538A3 (en) | Use of anti-amyloid beta antibody in ocular diseases | |
| JP2015504421A5 (en) | ||
| JP2011528561A5 (en) | ||
| WO2009048539A3 (en) | Use of anti-amyloid beta antibody in ocular diseases | |
| NO20093387L (en) | Antibody to IL-6 and its use | |
| JP2017518258A5 (en) | ||
| RU2018102606A (en) | MOLECULES RELATING TO PSL PSEUDOMONAS AND WAYS OF THEIR APPLICATION | |
| WO2019098763A3 (en) | ANTIBODIES TO α-SYNUCLEIN AND USES THEREOF | |
| MX2016004928A (en) | Cross-reactive staphylococcus aureus antibody sequences. | |
| WO2020121195A8 (en) | Trem2 antibodies and uses thereof | |
| WO2012009442A3 (en) | Anti-addl monoclonal antibody and uses thereof |